Company Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Autolus Therapeutics plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
4.21 ^USD	-6.03%		-13.02%	-34.63%

Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT
Apr. 18	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Number of employees: 467

USD in Million	2022	Weight	2023	Weight	Delta
Chimeric Antigen Receptors T Cell Therapies 100.0 %	6	100.0 %	2	100.0 %	-73.30%

USD in Million	2022	Weight	2023	Weight	Delta
United States 79.6 %	-	-	1	79.6 %	-
United Kingdom 20.4 %	-	-	0	20.4 %	-

Managers	Title	Age	Since
Martin Pulé FOU	Founder	51	14-08-31
Christian Martin Itin CEO	Chief Executive Officer	59	14-09-30
Robert Dolski DFI	Director of Finance/CFO	54	23-08-06
Veronica Hersberger CTO	Chief Tech/Sci/R&D Officer	-	23-03-31
David Brochu CTO	Chief Tech/Sci/R&D Officer	-	19-02-28
Christopher Vann COO	Chief Operating Officer	59	16-09-30
Julia Wilson IRC	Investor Relations Contact	-	-
Alexander Swan IRO	Public Communications Contact	-	21-09-30
Olivia Manser IRO	Public Communications Contact	-	22-02-28
Miranda Neville PRN	Corporate Officer/Principal	-	17-12-31

Members of the board	Title	Age	Since
John Berriman BRD	Director/Board Member	76	14-07-31
William Young BRD	Director/Board Member	79	21-11-14
Cynthia Butitta BRD	Director/Board Member	70	18-02-28
Martin Murphy BRD	Director/Board Member	55	14-08-31
Christian Martin Itin CEO	Chief Executive Officer	59	14-09-30
Linda Bain BRD	Director/Board Member	53	18-06-07
Robert Iannone BRD	Director/Board Member	57	23-06-19
Robert Azelby BRD	Director/Board Member	56	Jan. 08
Martin Pulé FOU	Founder	51	14-08-31
Elisabeth Leiderman BRD	Director/Board Member	47	Dec. 19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	265,926,305	8,823,530 ( 3.318 %)	0	3.318 %

Name	Equities	%	Valuation
Syncona Portfolio Ltd. 8.027 %	21,346,829	8.027 %	136 M $
Clarus Ventures LLC 7.703 %	20,485,611	7.703 %	131 M $
Qatar Investment Authority (Investment Management) 5.641 %	15,000,000	5.641 %	96 M $
Paradigm BioCapital Advisors LP 4.742 %	12,611,335	4.742 %	80 M $
Deep Track Capital LP 4.463 %	11,869,297	4.463 %	76 M $
Polygon Management Ltd. 3.008 %	8,000,000	3.008 %	51 M $
Woodford Investment Management Ltd. 2.466 %	6,557,082	2.466 %	42 M $
Cormorant Asset Management LP 2.049 %	5,450,000	2.049 %	35 M $
Armistice Capital LLC 1.448 %	3,850,000	1.448 %	25 M $
Adage Capital Partners GP LLC 1.439 %	3,825,532	1.439 %	24 M $

Name	Equities	%	Valuation
BIONTECH SE 20.06 %	33,333,333	20.06 %	213 M $
BLACKSTONE INC. 12.33 %	20,485,611	12.33 %	131 M $
PPF Group NV 8.796 %	14,612,275	8.796 %	93 M $
Syncona Partners LLP 7.332 %	12,180,333	7.332 %	78 M $
LSP Advisory BV 1.150 %	1,909,955	1.150 %	12 M $
Christian Martin Itin 0.6417 %	1,066,009	0.6417 %	7 M $
Martin Pulé 0.4206 %	698,741	0.4206 %	4 M $
Capital Research & Management Co. (World Investors) 0.3762 %	625,000	0.3762 %	4 M $
John Berriman 0.0821 %	136,331	0.0821 %	869 792 $
Christopher Vann 0.0675 %	112,211	0.0675 %	715 906 $

Autolus Therapeutics Plc

The Mediaworks 191 Wood Lane

W12 7FP, London

+44 20 3829 6230

http://www.autolus.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.21 USD

Average target price

10.54 USD

Spread / Average Target

+150.46%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AUTOLUS THERAPEUTICS PLC	-34.63%	1.12B
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs